Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

PHASE3UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
Raynaud Disease
Interventions
DRUG

0.9% nitroglycerin in TAM cream

0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures

DRUG

vehicle cream

0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures

Trial Locations (11)

28401

Carolina Arthritis, Wilmington

43614

University of Toledo, Toledo

44195

Cleveland Clinic, Cleveland

48106

University of Michigan, Ann Arbor

49546

Michigan State University, Grand Rapids

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

94063

Stanford University, Redwood City

06030

University of Connecticut, Farmington

02114

Massachusetts General Hospital, Boston

08903

University of Medicine and Dentistry in New Jersey, New Brunswick

Sponsors
All Listed Sponsors
lead

MediQuest Therapeutics

INDUSTRY